Literature DB >> 28330111

Effect of STAT3 inhibitor in chronic myeloid leukemia associated signaling pathway: a mathematical modeling, simulation and systems biology study.

Himansu Kumar1, Swapnil Tichkule1, Utkarsh Raj1, Saurabh Gupta1, Swati Srivastava1, Pritish Kumar Varadwaj2.   

Abstract

Chronic myeloid leukemia (CML) is a hematopoietic stem-cell disorder which proliferates due to abnormal growth of basophil cells. Several proangiogenic molecules have been reported to be associated in CML progression, including the hepatocyte growth factor (HGF). However, detail mechanism about the cellular distribution and function of HGF in CML is yet to be revealed. The proliferation of hematopoietic cells are regulated by some of the growth factors like interleukin 3 (IL-3), IL-6, erythropoietin, thrombopoietin, etc. In this study IL-6 pathways have been taken into consideration which induces JAK/STAT and MAPK pathways to decipher the CML progression stages. An attempt has been made to model these pathways with the help of ordinary differential equations (ODEs) and estimating unknown parameters through fminsearch optimization algorithm. Some of the specific component like STAT3, of the pathway has been analyzed in detail and their role in CML progression has been elucidated. The roles of STAT3 inhibitors into the treatment of CML have been thoroughly studied and optimum concentration of the inhibitors have been predicted.

Entities:  

Keywords:  HGF; IL6; JAK/STAT and MAPK pathways; ODE’s

Year:  2016        PMID: 28330111      PMCID: PMC4729759          DOI: 10.1007/s13205-015-0357-7

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.406


  27 in total

Review 1.  BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.

Authors:  Xin An; Amit K Tiwari; Yibo Sun; Pei-Rong Ding; Charles R Ashby; Zhe-Sheng Chen
Journal:  Leuk Res       Date:  2010-10       Impact factor: 3.156

2.  Modeling regulatory mechanisms in IL-6 signal transduction in hepatocytes.

Authors:  Abhay Singh; Arul Jayaraman; Juergen Hahn
Journal:  Biotechnol Bioeng       Date:  2006-12-05       Impact factor: 4.530

Review 3.  New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.

Authors:  Hagop M Kantarjian; Moshe Talpaz; Francis Giles; Susan O'Brien; Jorge Cortes
Journal:  Ann Intern Med       Date:  2006-12-19       Impact factor: 25.391

4.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

5.  Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression.

Authors:  Sabine Cerny-Reiterer; Viviane Ghanim; Gregor Hoermann; Karl J Aichberger; Harald Herrmann; Leonhard Muellauer; Andreas Repa; Christian Sillaber; Andrew F Walls; Matthias Mayerhofer; Peter Valent
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

6.  A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.

Authors:  Xiaolei Zhang; Peibin Yue; Steven Fletcher; Wei Zhao; Patrick T Gunning; James Turkson
Journal:  Biochem Pharmacol       Date:  2010-01-11       Impact factor: 5.858

7.  Control mechanism of JAK/STAT signal transduction pathway.

Authors:  Satoshi Yamada; Satoru Shiono; Akiko Joo; Akihiko Yoshimura
Journal:  FEBS Lett       Date:  2003-01-16       Impact factor: 4.124

Review 8.  Mathematical modeling of intracellular signaling pathways.

Authors:  Edda Klipp; Wolfram Liebermeister
Journal:  BMC Neurosci       Date:  2006-10-30       Impact factor: 3.288

9.  Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.

Authors:  Anna M Eiring; Brent D G Page; Ira L Kraft; Thomas O'Hare; Patrick T Gunning; Michael W Deininger; Clinton C Mason; Nadeem A Vellore; Diana Resetca; Matthew S Zabriskie; Tian Y Zhang; Jamshid S Khorashad; Alexander J Engar; Kimberly R Reynolds; David J Anderson; Anna Senina; Anthony D Pomicter; Carolynn C Arpin; Shazia Ahmad; William L Heaton; Srinivas K Tantravahi; Aleksandra Todic; Richard Moriggl; Derek J Wilson; Riccardo Baron
Journal:  Leukemia       Date:  2014-08-19       Impact factor: 11.528

10.  Narrative-based computational modelling of the Gp130/JAK/STAT signalling pathway.

Authors:  Maria Luisa Guerriero; Anna Dudka; Nicholas Underhill-Day; John K Heath; Corrado Priami
Journal:  BMC Syst Biol       Date:  2009-04-15
View more
  2 in total

1.  Overexpression of miR-574-3p suppresses proliferation and induces apoptosis of chronic myeloid leukemia cells via targeting IL6/JAK/STAT3 pathway.

Authors:  Haoying Yang; Jun Zhang; Jiuping Li; Furong Zhao; Yao Shen; Xuemei Xing
Journal:  Exp Ther Med       Date:  2018-09-05       Impact factor: 2.447

2.  Computational quantification of global effects induced by mutations and drugs in signaling networks of colorectal cancer cells.

Authors:  Sara Sommariva; Giacomo Caviglia; Silvia Ravera; Francesco Frassoni; Federico Benvenuto; Lorenzo Tortolina; Nicoletta Castagnino; Silvio Parodi; Michele Piana
Journal:  Sci Rep       Date:  2021-10-01       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.